Novartis's COPD therapy QVA149 impresses the experts in Vienna; Stem cell treatment credited with restoring sensory function in spinal cord patients;

 @FierceBiotech: Penn grabs Agios deal, settling high-profile IP theft claim. Report | Follow @FierceBiotech

 @JohnCFierce: Offbeat: Pulmatrix's Robert Connelly leaves to helm WikiCell, creating "delicious" food packaging; The startup has Flagship, Polaris backing. Release | Follow @JohnCFierce

> Reuters profiles Novartis' ($NVS) challenge of GlaxoSmithKline's ($GSK) leading role in the COPD market as QVA149 stole the show in Vienna. GSK and Theravance ($THRX) have been advanced a second-gen drug of their own, but so far have failed to win over skeptics. Story

> In a small study of patients with spinal cord damage, StemCells reports that its stem cell treatment helped restore "sensory function" in two of three subjects. Story

> The European Commission has approved an application from Takeda Pharmaceutical and NPS Pharmaceuticals to market teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome. Release

> Industrial enzyme-maker Codexis has slashed 133 staffers and adopted a poison pill defense after Royal Dutch Shell terminated a pact. The enzymes are used in fuel and pharmaceutical processes. Story

> Sanofi's ($SNY) buyback of contingent value rights is signaling its confidence in the future of Lemtrada, a new MS treatment. Story

Pharma News

 @FiercePharma: Here's more on the 'gutter oil' scandal in China, allegedly used to make antibiotics. Report | Follow @FiercePharma

> J&J's Zytiga gets early challenge from Medivation's new pill. Article

> Merck KGaA lines up 1,100 German jobs for the ax. Story

> Valeant puts $2.6B more skin in the dermatology game with Medicis buy. More

Medical Device News

 @FierceMedDev: Watch out, Medtronic, BSX and the rest, researchers have developed a pacemaker that fits on the head of a pin. Story | Follow @FierceMedDev

 @MarkHFierce: So, non-invasive Dx imaging costs for Medicare Part B actually went down from 2006-10. Not so pricey after all. Release | Follow @MarkHFierce

 @DamianFierce: Philips Healthcare's Respironics is conducting its second ventilator recall in as many months. Story | Follow @DamianFierce

> ConvaTec snags catheter maker for $321M. News

> Medicare Dx costs enjoy steady drop. Item

> I-Flow recalls infusion pumps over deadly flaw. News

CRO News

> U.K.'s NHS considers commercial services; Big Pharma intrigued. Report

> Hospira drops $200M on Indian API plant. News

> Indian regulator wants to expand its ranks. More

> Charles River snaps up Accugenix for $17M. Story

Pharma Manufacturing News

> 2 Merck KGaA production facilities whacked in cuts. Article

> Dangers aside, drugmakers can't live without Chinese APIs. Story

Biotech IT News

> Merck Serono bioinformatics head starts new company. Item

> PerkinElmer partners with MGH on informatics system for cancer research. Article

> Video game players take on deadly sepsis for U.S. military. Story

> CLC bio buys molecular docking software company Molegro. News

> Tech startup waltzes with wireless giant in Africa to expand mobile anti-drug counterfeiting system. More

Biotech Research News

> Worm stem cells carry tissue regeneration clues. Report

> Johns Hopkins scientists produce protein that helps track tumors. Item

> Roche/Genentech drug beats back treatment-resistant breast cancer cells. Article

> Cleveland Clinic's Alzheimer's drug makes strong preclinical debut. More

> Gene therapy rebuilds sense of smell in mice. Story

And Finally… New animal research shows that heavy drinking rewires the brain in ways that makes it harder for alcoholics to recover from a traumatic experience. Release

 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.